





European Union

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003673

2021 COVID-19 vaccine effectiveness against hospitalisation due to laboratory-confirmed SARS-CoV-2 infection in older adults: pre-Delta and Delta periods Pooled results from nine European countries

15 December 2021

ECDC & I-MOVE-COVID-19 hospital VE networks

- 15 European study sites in COVID-19 VE*
 0 48 hospitals collecting information
- Aim to measure COVID-19 VE among hospitalised SARI patients in vaccine target group overall and by vaccine product

 among those aged 60+ for this analysis
- Secondary objectives
 - VE against variants
 - VE by age group, risk group, doses
 - \circ VE by delay between doses, over time

Navarra, ES FR RO PΤ ES

https://www.ecdc.europa.eu/sites/default/files/documents/Core-protocol-for-ECDC-studies-of-COVID-19-vaccine-effectiveness-against-hospitalisation-with-SARI.pdf https://www.imoveflu.org/wp-content/uploads/2021/03/08feb2021_draft_generic_VE_protocol_hospital-based_COVID-19_v07.pdf

^{*}Draft generic protocols available online:

Methods

- Test-negative design
 - \odot SARI patients* are swabbed
 - o case: SARS-CoV-2 positive; control: SARS-CoV-2 negative
- PCR test only

 \circ swabbed within 10 days of symptom onset

- Restriction to target group for vaccination at time of swab
- Vaccination definitions

 \circ one dose only: receipt of only 1 dose of 2-dose vaccines \geq 14 days before onset

 \bigcirc at least one dose: receipt of ≥1 dose ≥14 days before symptom onset

○ completely vaccinated: receipt of 2 doses (1 dose if Janssen) ≥ 14 days before onset

 \odot booster dose: not included in this analysis

*ECDC possible COVID-19: hospital 24 hrs + fever/cough/shortness of breath/sudden onset anosmia/ageusia/dysgeusia; WHO SARI: ARI + hospital + fever+cough + onset <=10 days

Methods


- Study periods: pre-Delta and Delta dominated
 - 26 Dec 2020–31 May 2021 (June excluded as transition)
 - 01 July 2020–30 Sep 2021
- Logistic regression, study site as fixed effect

 adjusted for age, date of swab, sex, presence of any common chronic conditions*
- VE: (1-OR)*100
- Stratified by age-groups

 overall and product-specific analyses: 60–79, 80+ years
- Complete vaccination with primary course (no boosters)
- Analytic exclusions
 - \circ sites dropped from analysis if <5 eligible cases and controls
 - \circ VE estimated using penalised logistic regression (Firth's method)
 - to check for sparse data bias
 - $_{\odot}$ VE point estimates not shown if <20 vaccinated cases and controls

*Four chronic conditions common to all sites: diabetes (metabolic syndrome in ES), heart disease, lung disease, asthma (last two combined for ES)

Recruitment and exclusions (data from 12 sites*)




6,625 Excluded

- aged <60 years
- not eligible for vaccination
- swabbed >10 days after onset
- in long-term care facility
- vaccinated within 14 days of onset
- missing/incorrect vaccination information or not vaccinated with recommended dose delay
- swabbed during June (transition month)
- onset date >3 days after swab
- missing onset date
- **99** tested negative at admission but positive previously
- missing sex (50) or age (24)
- health care workers
- duplicate

*Data from 44 hospitals

Recruitment and exclusions (data from 12 sites*)



*Data from 44 hospitals

61

Unvaccinated


468

Unvaccinated

723

411

Cases and controls by week of swab, and first dose of COVID-19 vaccine ECDC & I-MOVE COVID-19 VE hospital studies, Europe, 26 Dec 2020–30 Sep 2021 (N=3,271)



Patient characteristics: age, sex and chronic conditions ECDC & I-MOVE COVID-19 VE hospital studies, Europe, 26 Dec 2020–31 May 2021 (N=2,073) pre-Delta period

		Cases (N=1,350)		Contro	ls (N=723)
		Ν	%	Ν	%
Median age (years)		75 yrs		80 yrs	
Age groups	60–79	853	63	342	47
	80+	497	37	381	53
Sex	Male	751	56	394	54
	Female	599	44	329	46
Chronic	Yes	946	63	556	77
conditions*	No	496	37	167	23

*Any one of diabetes, heart disease, lung disease, asthma.

Patient characteristics: age, sex and chronic conditions ECDC & I-MOVE COVID-19 VE hospital studies, Europe, 01 Jul–30 Sep 2021 (N=968) *Delta period*

		Cases (N=557)		Controls	Controls (N=411)	
		Ν	%	Ν	%	
Median age (years)		74 yrs		79 yrs		
Age groups	60–79	369	66	211	51	
	80+	188	34	200	49	
Sex	Male	286	51	239	58	
	Female	271	49	172	42	
Chronic	Yes	319	57	309	75	
conditions*	No	238	43	102	25	

*Any one of diabetes, heart disease, lung disease, asthma.

Patient characteristics: vaccination status ECDC & I-MOVE COVID-19 VE hospital studies, Europe, 26 Dec 2020–31 May 2021 (N=2,071) pre-Delta period

		Cases (n=1,348)		Controls (n=723)	
		No.	%	No.	%
COVID vaccina	tion:				
any	No	1,255	93	468	65
	Yes	93	7	255	35
COVID vaccina	tion:				
doses	None	1,255	93	468	65
	One	77	6	123	17
	Two	16	1	132	18
	Three	0	0	0	0

Patient characteristics: vaccination status ECDC & I-MOVE COVID-19 VE hospital studies, Europe, 01 Jul–30 Sep 2021 (N=968) *Delta period*

		Cases (n=557)		Controls (n=411)	
		No.	%	No.	%
COVID vaccina	ation:				
any	No	329	59	61	15
	Yes	228	41	350	85
COVID vaccina	ation:				
doses	None	329	59	61	15
	One	45	8	21	5
	Two	183	33	329	80
	Three	0	0	0	0


Patient characteristics: vaccine product ECDC & I-MOVE COVID-19 VE hospital study, Europe, 26 Dec 2020–31 May 2021 (N=348) pre-Delta period

		Vaccinated cases (n=93)		Vaccinated controls (n=255)	
		No.	%	No.	%
First dose	Comirnaty	60	65	205	80
	Vaxzevria	25	27	33	13
	Spikevax	7	8	13	5
	Curevac	0	0	0	0
	Janssen	0	0	1	<1
	Unknown	1	1	3	1
Second dose	Comirnaty	15	94	129	98
	Vaxzevria	0	0	0	0
	Spikevax	1	6	3	2
	Curevac	0	0	0	0
	Unknown	0	0	0	0

Patient characteristics: vaccine product ECDC & I-MOVE COVID-19 VE hospital study, Europe, 01 Jul–30 Sep 2021 (N=578) Delta period

		Vaccinated cases (n=228)		Vaccinated controls (n=350)	
		No.	%	No.	%
First dose	Comirnaty	155	68	270	77
	Vaxzevria	31	14	35	10
	Spikevax	7	3	19	5
	Janssen	19	8	9	3
	Curevac	1	<1	1	<1
	Unknown	15	7	16	5
Second dose	Comirnaty	147	80	263	80
	Vaxzevria	19	10	31	9
	Spikevax	6	3	18	5
	CVnCoV	0	0	1	<1
	Unknown	11	6	16	5


COVID-19 vaccine effectiveness among hospitalised patients (all vaccine types) in target group for vaccination aged 60+ at swab date by age-group, complete primary dose ECDC & I-MOVE COVID-19 VE hospital study, Europe, 27 Dec 2020–30 Sep 2021*



Period of swab for SARI patients overall and by age group

8 sites: BE, ES, FR, HR, LT, MT, NA, NL (26 Dec 2020-31 May 2021); BE, ES, FR, HR, LT, MT, NA, PT (01 Jul-30 Sep 2021) *Adjusted by site, sex, age, month of swab, $\geq 1/4$ common chronic conditions

COVID-19 vaccine effectiveness among hospitalised patients (Comirnaty vaccine) in target group for vaccination aged 60+ at swab date by age-group, complete primary dose ECDC & I-MOVE COVID-19 VE hospital study, Europe, 27 Dec 2020–30 Sep 2021*



7 sites: BE, ES, FR, HR, MT, NA, NL (26 Dec 2020-31 May 2021); 8 sites: BE, ES, FR, HR, LT, MT, NA, PT (01 Jul-30 Sep 2021) *Adjusted by site, sex, age, month of swab, $\geq 1/4$ common chronic conditions

Discussion

- VE >80% observed in both periods of 2021 for 60+ years
- Lower VE in later (Delta-dominant) than pre-Delta period for 60+ years

 83% (95%CI 73–89) vs 93% (95%CI 87–97)
 higher vaccine coverage during Delta than pre-Delta period
- 60–79 year olds have higher VE than 80+
 o note: only one vaccinated case among 60–79 year olds in pre-Delta period
- Particularly lower VE in Delta period for the oldest age group (80+)
 87% (95%CI 73–94) vs 55% (95%CI 7–79: very wide Cls)
 - clinically extremely vulnerable?
 - waning of primary course of vaccination greater/faster in older individuals?
 - very high vaccine coverage in 80+ (targeted first for vaccination)

➤ are unvaccinated representative ?

Conclusion

- COVID-19 vaccination provides significant protection at hospital level among those aged 60+
 - 9 in 10 persons aged 60+ could avoid hospitalisation in pre-Delta period by having completed a primary vaccine course (8 in 10 for Delta period)
 this remains true even in the Delta dominant period *for those aged 60–79*

Challenges

- Only Comirnaty with enough sample size for product-specific
- Limited sequencing
- Representativeness of unvaccinated as vaccination coverage increases
- Site challenges with sample size
 - \circ very few/no controls in some sites
 - o case numbers declining with increased vaccination (vaccinated case numbers very low)
 - suggests that vaccination is working against hospitalisation

Next steps

- Study ongoing
 in future analyses: VE over time and by
 - o booster dose(s)
 - \odot time since vaccination
 - \circ delay between doses
 - \odot other vaccine products
 - \circ variant(s)
 - o other outcomes (ICU admission, death)
- Pooling with other TND VE networks

Thank you especially to all participants, hospital staff, and study sites

Study participants

- Study sites ECDC & I-MOVE COVID-19 hospital VE networks
 - Albania, IPH: S Bino, I Hasibra, A Simaku, V Adela, E Nelaj, I Preza
 - Belgium, UZB: L Seyler, T Demuyser E Van Nedervelde
 - Belgium, Sciensano: N Bossuyt, I Thomas, B Lissoir, K Magerman, M Bourgeois, N Fischer, N Dauby, M Reynders, S Denayer
 - France, REIVAC: O Launay, F Laine, A Pini, F Galtier, P Vanhems, Z Lesieur, N Lenzi, LB Luong, Y Saidi, S Amour, LB Luong
 - France, SPF: D Levy-Bruhl, A Pini, A Maisa, S Bernard-Stoecklin
 - Greece, NIPH (EODY): S Michelaki, M Amerali
 - Croatia, NIPH: G Petrović, Z Lovrić Makarić, I Pem Novosel, P Smoljo
 - **Czechia, PHI:** H Orlíková
 - Czechia, UH Brno: P Husa, L Součková
 - Ireland, HPSC: L Domegan, A Cotter, N Petty Saphon, M Brady
 - Lithuania, UnL: G Gefenaite, I Jonikaite, M Kuliese, A Mickiene
 - Luxembourg, MoH: N Aouali, G Fagherazzi, A Al Kerwi, F Berthet, M Alexandre
 - Malta, HPDPD: J Baruch, JP Cauchi, M-L Borg, A Dziugyte, T Melillo
 - Netherlands: A Niessen, M Knol
 - Portugal, INSA: B Nunes, A Machado, R Guiomar, A Rodrigues, V Gomez, I Kislaya, V Gaio
 - Romania, Cantacuzino: M Lazar, I Loghin, A Marin, E Duca
 - Spain, ISPL, Navarra: J Castilla, C Burgui Alcaide, I Casado Buesa
 - Spain, National Centre for Epidemiology (CNE), ISCIII: A Larrauri, C Mazagatos Ateca
 - **Spain, National Centre for Microbiology (CNM), ISCIII**: F Pozo, V Sandonis, I Casas
- Epiconcept: M Valenciano, A Moren, A Nardone, E Kissling, V Nancey, D Marques, K Voy
- ECDC: S Bacci, C Carstairs, N Nicolay
- EC: S Sowinski, C Pereira, E Depoortere
- WHO/EURO: R Pebody, M Katz, P Jorgensen